ESR1 and breast cancer: The results from the above 2 studies in which the AR/ER ratio was used to estimate prognosis in patients with primary luminal BC (i.e., ER+/HER2-) raises the question as to whether this new parameter will become mandatory for prognostic classification in this BC subset.